BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 10635303)

  • 1. [Detection of serum p53 antibodies in colorectal cancer patients and the clinical significance of postoperative monitoring].
    Takeda A; Shimada H; Nakajima K; Imaseki H; Okazumi S; Takayama W; Hayashi H; Iwasaki K; Sasagawa S; Chou A; Natsume T; Kouno T; Kondou S; Maeda T; Hori S; Suzuki T; Ochiai T; Isono K
    Gan To Kagaku Ryoho; 1999 Dec; 26(14):2189-94. PubMed ID: 10635303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of blood-borne cells in colorectal cancer patients by nested reverse transcription-polymerase chain reaction for carcinoembryonic antigen messenger RNA: longitudinal analyses and demonstration of its potential importance as an adjunct to multiple serum markers.
    Guadagni F; Kantor J; Aloe S; Carone MD; Spila A; D'Alessandro R; Abbolito MR; Cosimelli M; Graziano F; Carboni F; Carlini S; Perri P; Sciarretta F; Greiner JW; Kashmiri SV; Steinberg SM; Roselli M; Schlom J
    Cancer Res; 2001 Mar; 61(6):2523-32. PubMed ID: 11289125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum p53 antibody is a useful tumor marker in superficial esophageal squamous cell carcinoma.
    Shimada H; Takeda A; Arima M; Okazumi S; Matsubara H; Nabeya Y; Funami Y; Hayashi H; Gunji Y; Suzuki T; Kobayashi S; Ochiai T
    Cancer; 2000 Oct; 89(8):1677-83. PubMed ID: 11042560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increase in both CEA and CA19-9 in sera is an independent prognostic indicator in colorectal carcinoma.
    Nozoe T; Rikimaru T; Mori E; Okuyama T; Takahashi I
    J Surg Oncol; 2006 Aug; 94(2):132-7. PubMed ID: 16847905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer.
    Reiter W; Stieber P; Reuter C; Nagel D; Lau-Werner U; Lamerz R
    Anticancer Res; 2000; 20(6D):5195-8. PubMed ID: 11326694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Detection and clinical study of serum tumor markers in patients with colorectal cancer].
    Zhao XW; Jiang B; Han CZ; Jing JX
    Zhonghua Zhong Liu Za Zhi; 2005 May; 27(5):286-8. PubMed ID: 15996321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative analysis of predictive biomarkers for therapeutical strategies in colorectal cancer.
    Gasser M; Gerstlauer C; Grimm M; Bueter M; Lebedeva T; Lutz J; Maeder U; Ribas C; Ribas C; Nichiporuk E; Thalheimer A; Heemann U; Thiede A; Meyer D; Waaga-Gasser AM
    Ann Surg Oncol; 2007 Apr; 14(4):1272-84. PubMed ID: 17211733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinico-pathological characteristics of colorectal cancer and serum anti-p53 antibodies.
    Bielicki D; Karbowniczek M; Sulzyc-Bielicka V; Kładny J; Boer C; Marlicz K; Domagała W
    Pol J Pathol; 1999; 50(2):77-81. PubMed ID: 10481530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Serum anti-p53 antibodies and CEA in monitoring of recurrences of colorectal cancer].
    Bielicki D; Sulzyc-Bielicka V; Domagała W
    Ann Acad Med Stetin; 2008; 54(3):99-104. PubMed ID: 19839520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the diagnostic value of serum tumor markers, and fecal k-ras and p53 gene mutations for pancreatic cancer.
    Wu X; Lu XH; Xu T; Qian JM; Zhao P; Guo XZ; Yang XO; Jiang WJ
    Chin J Dig Dis; 2006; 7(3):170-4. PubMed ID: 16808798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of three hepatitis markers (p53 antibodies, vascular endothelial growth factors and alpha fetoprotein) in patients with hepatocellular carcinoma.
    Gadelhak NA; Gadelhak SA; El-Morsi DA; Abdelaziz MM; Abbas AT; El-Emshaty HM
    Hepatogastroenterology; 2009; 56(94-95):1417-24. PubMed ID: 19950803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic alteration of p53, but not overexpression of intratumoral p53 protein, or serum p53 antibody is a prognostic factor in sporadic colorectal adenocarcinoma.
    Chang SC; Lin JK; Lin TC; Liang WY
    Int J Oncol; 2005 Jan; 26(1):65-75. PubMed ID: 15586226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is it reasonable to add preoperative serum level of CEA and CA19-9 to staging for colorectal cancer?
    Chen CC; Yang SH; Lin JK; Lin TC; Chen WS; Jiang JK; Wang HS; Chang SC
    J Surg Res; 2005 Apr; 124(2):169-74. PubMed ID: 15820244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical significance of serum anti-p53 antibody measurement for colorectal cancer].
    Kuwabara K; Kumamoto K; Ishibashi K; Ohsawa T; Kumagai Y; Baba H; Tsuji Y; Haga N; Ishida H
    Gan To Kagaku Ryoho; 2012 Nov; 39(12):2167-9. PubMed ID: 23268012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of colonoscopy on tumor markers.
    Scapa E; Broide E; Pinhasov I
    Surg Laparosc Endosc; 1997 Dec; 7(6):477-9. PubMed ID: 9438630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Testing for anti-p53 antibodies increases the diagnostic sensitivity of conventional tumor markers.
    Müller M; Meyer M; Schilling T; Ulsperger E; Lehnert T; Zentgraf H; Stremmel W; Volkmann M; Galle PR
    Int J Oncol; 2006 Oct; 29(4):973-80. PubMed ID: 16964393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of postoperative survival by preoperative serum concentrations of anti-p53 compared to CEA, CA 50, CA 242 and conventional blood tests in patients with colorectal carcinoma.
    Forslund A; Engarås B; Lönnroth C; Lundholm K
    Int J Oncol; 2002 May; 20(5):1013-8. PubMed ID: 11956598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Usefulness of preoperative assay CEA and CA 19-9 in colorectal cancer patients].
    Grotowski M; Maruszyński M; Piechota W
    Pol Merkur Lekarski; 2001 Dec; 11(66):476-9. PubMed ID: 11899841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Normal and modified urinary nucleosides represent novel biomarkers for colorectal cancer diagnosis and surgery monitoring.
    Feng B; Zheng MH; Zheng YF; Lu AG; Li JW; Wang ML; Ma JJ; Xu GW; Liu BY; Zhu ZG
    J Gastroenterol Hepatol; 2005 Dec; 20(12):1913-9. PubMed ID: 16336453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application of C12 multi-tumor marker protein chip in the diagnosis of gastrointestinal cancer: results of 329 surgical patients and suggestions for improvement.
    Yang XQ; Yan L; Chen C; Hou JX; Li Y
    Hepatogastroenterology; 2009; 56(94-95):1388-94. PubMed ID: 19950797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.